Sharewise Presentation 22/7/24, page-14

Makes sense interested parties would wait now until FDA clearance. Cost of bringing drugs to market currently anywhere between $350-500 USD million or more but depends. Perhaps PAR have been a little optimistic along the way with cost estimates, p/ship potential and raising less than necessary when the SP was higher. If I was on the sidelines till now I would be waiting also for FDA approval but after that, 30c seems a good play IMO (doesn't help longer term holder's however). I get the up front money is probably more important right now but it would have been nice if they kept more margin at least for Aus/NZ. I've seen a few biotechs end up with relative peanuts after all the slog. Understand partner's in China and USA would make sense though. Just need that FDA clearance right now. GLTA